Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 India's Lupin Recalls 10,000 Bottles of Suprax in the U.S. | Contract Pharma
Breaking News

India’s Lupin Recalls 10,000 Bottles of Suprax in the U.S.

antibiotic fails to meet U.S. standards for impurities

Lupin Pharmaceuticals Inc., based in Baltimore, MD has recalled 10,000 bottles of the antibiotic Suprax made by its Indian parent company, Lupin Ltd., after failing to meet U.S. standards for impurities. The recall was initiated on January 27 but made public by the U.S. FDA this week. Suprax is used to treat bacterial infections of the ear and upper respiratory tract.
 
“This is a voluntary recall initiated on our own and of no business consequence,” according to a Lupin spokesman in India.
 
As the second-largest supplier of generic drugs in the U.S., the U.S. FDA has increased its scrutiny of Indian pharmaceutical companies the past few years and has since uncovered numerous quality issues.
 
Lupin joins India’s Ranbaxy Laboratories Ltd. and Sun Pharmaceutical Industries Ltd. for recent product recalls, including 480,000 bottles of generic versions of the cholesterol drug Lipitor in the U.S. due to glass particles found in some bottles, and Sun Pharma’s recall of thousands of bottles of generic diabetes medication in the U.S. after some bottles were found to contain drugs meant to treat epilepsy.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters